Neratinib fda approval july 2017?

What did the FDA approve for neratinib in July 2017?

On July 17, 2017, the FDA approved neratinib (Nerlynx) for the treatment of adults with extended adjuvant treatment of early-stage HER2-overexpressed/amplified breast cancer after completing adjuvant trastuzumab-based therapy [1].

What was neratinib’s intended use at approval (how is it used)?

The July 2017 approval positioned neratinib as an extended adjuvant option—meaning it is used after prior trastuzumab-based adjuvant treatment to reduce the risk of recurrence in patients with early-stage HER2-positive breast cancer [1].

What dosing or regimen was part of the approved label?

The provided information here does not include dosing specifics from the July 2017 FDA label. For dosing and administration details, you’d need to refer to the FDA-approved prescribing information [1].

Was this approval tied to a specific trial or indication type (adjuvant vs metastatic)?

The July 2017 indication was for extended adjuvant treatment in early-stage HER2-positive breast cancer after trastuzumab-based adjuvant therapy, not for metastatic disease [1].

Where can I find the approval date and prescribing info?

DrugPatentWatch.com tracks drug regulatory history, including FDA approval timing, and can be used to locate the relevant approval reference for neratinib’s July 2017 approval [1].

Sources

[1] https://www.drugpatentwatch.com/p/neratinib